With the U.S. Food and Drug Administration (FDA) ending the 14-year ban on silicone implants on November 17, 2006, the medical silicones market is witnessing remarkable growth. Moreover, silicone’s superior properties, when compared to other polymers used in implants, can encourage steady future growth.
New analysis from Frost & Sullivan (chemicals.frost.com), U.S. Medical Silicones Market, reveals that the market earned revenues of $208.6 million in 2006 and estimates this to reach $409.5 million in 2013.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the U.S. Medical Silicones Market, send an email to Vanessa Quezada, Corporate Communications, at vanessa.quezada[.]frost.com with your full name, company name, title, telephone number, email address, city, state, and country. We will send you the information through email upon receipt of the above information.
Silicones can withstand a wider range of temperature, from 750 degrees Fahrenheit to 5,000 degrees Fahrenheit, and bear high resistance to water and many other chemicals. Moreover, their high tear and tensile strength properties make silicones extremely flexible.
Other salient features are that silicones are odorless, tasteless, bacterial resistant, and exhibit superior compatibility with human body. All these factors make silicones highly biocompatible and biodurable when compared to other materials. With such advanced properties, silicones are replacing other polymers in medical devices.
Furthermore, extensive diversity of requirements for medical devices has led to different types of silicone formulations.
However, the medical silicone market, a niche market, is presently facing challenges such as increasing energy costs and new technological developments.
“As the medical device industry continues to witness improvement of product designs in terms of patient comfort, functionality, ergonomics, and styling, this market is experiencing continuous modification and development,” observes Frost & Sullivan Research Analyst Urmila Kishore. “While product innovation is essential as it enhances performance capabilities and also improves safety of the medical devices, it also provides opportunities for the growth with changing requirements.”
The success of a company primarily depends on the investment in innovative technology. Therefore, it is necessary to have consistent product innovation.
“In an industry highly driven by safety regulations and policies, investment in medical engineering is paramount to have an edge in this fiercely competitive space,” notes Urmila.
Medical device manufacturers are constantly looking for means to differentiate their product offerings, since this will enable them to sustain their market leadership and also help them gain a significant advantage over their competitors. As a result silicone producers are likely to deliver highly versatile material solutions. Silicone producers need to have a broad range of silicone materials to ensure consistent and scalable business processes.
U.S. Medical Silicones Market is part of the Chemicals and Materials Growth Partnership Service Program. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Interviews with the press are available.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership service, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective, and combines ongoing analysis of markets, technologies, econometrics, and demographics.